Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [ID1259]

  • In development
  • GID-TA10225
  • Expected publication date: TBC

Status:
In progress
Technology type:
Medicine
Decision:
Prioritised
Process:
STA Standard

Timeline

Key events during the development of the guidance:

Date Update
11 August 2017 In progress. In progress

For further information on our processes and methods, please see our CHTE processes and methods manual